Please assess the completion status of the following clinical trial:

Trial Title: SAFE-PCI for Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have the capacity to understand and sign an informed consent form~* Age ≥ 18 years~* Female patient undergoing urgent or elective PCI or undergoing diagnostic angiography to evaluate ischemic symptoms with the possibility of PCI~Exclusion Criteria:~* Peripheral arterial disease that prohibits vascular access~* Bilateral abnormal Barbeau tests~* Hemodialysis access (arteriovenous fistula or graft) in the arm to be used for PCI in case of assignment to radial approach (note that the opposite arm may be used for radial access in case a dialysis graft is present in one arm provided that the opposite arm has a normal Barbeau test)~* International normalized ratio (INR) ≥ 1.5 in a patient treated with oral vitamin K antagonists (i.e., warfarin).~* Receipt of oral Factor Xa or IIa inhibitors ≤ 24 hours prior to the procedure~* Planned staged PCI within 30 days of index procedure~* Valvular heart disease requiring valve surgery~* Planned right-heart catheterization~* Primary PCI for ST-segment elevation myocardial infarction~* Presence of bilateral internal mammary artery coronary bypass grafts~* Unable to provide informed consent~* Participation in any investigational drug or device study currently or within 30 days prior to enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transradial PCI (Type: OTHER): None
- Transfemoral PCI (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).